CYP4F11 is a cytochrome P450 monooxygenase predominantly expressed in liver that catalyzes oxidative metabolism of endogenous lipids and xenobiotics. The enzyme performs omega-hydroxylation of fatty acids and their oxygenated derivatives, inserting one oxygen atom into substrates while reducing the second to water, with electrons supplied by NADPH via cytochrome P450 reductase. CYP4F11 efficiently catalyzes terminal carbon oxidation of 3-hydroxy fatty acids such as 3-hydroxystearate and 3-hydroxypalmitate, producing their omega-hydroxylated metabolites that likely participate in long-chain 3-hydroxydicarboxylic acid biosynthesis 1. The enzyme also omega-hydroxylates and inactivates vitamin K forms (phylloquinone and menaquinone-4), which serve as cofactors in blood coagulation, with CYP4F11 and CYP4F2 equally efficient at this reaction 2. CYP4F11 metabolizes arachidonic acid and generates 20-hydroxyeicosatetraenoic acid (20-HETE), a lipid mediator that promotes cell proliferation 3. CYP4F11 is significantly overexpressed in hepatocellular carcinoma patients with NRF2 pathway activation and in lung squamous cell carcinoma, where it drives tumor progression through 20-HETE production; CYP4F11 knockdown suppresses cancer cell growth and enhances sorafenib sensitivity 4, 3. These findings position CYP4F11 and its 20-HETE synthesis pathway as potential therapeutic targets, with compounds like HET0016 demonstrating inhibitory potential in preclinical models.